APOE ε4 Genotype and the Risk for Subjective Cognitive Impairment in Elderly Persons
Publication: The Journal of Neuropsychiatry and Clinical Neurosciences
Abstract
The authors compared the risk for subjective cognitive impairment (SCI) between carriers of the apolipoprotein E ε4 (APOE ε4) allele (cases) and APOE ε4 noncarriers (controls). SCI was assessed by a validated self-reported questionnaire. The authors used multivariable logistic regression analyses to compute odds ratios and 95% confidence intervals adjusted for age, sex, education, and marital status. Data were available on 114 participants (83 women; 47 APOE ε4 carriers; mean age, 69 years). The risk for SCI was significantly higher among cases than controls, particularly for those 70 years of age and older. These findings should be considered preliminary until confirmed by a prospective cohort study.
There is a growing interest in the identification of the presymptomatic phase of Alzheimer’s disease (AD).1,2 One construct that refers to the incipient stage of AD and may constitute a high-risk state for dementia is subjective cognitive impairment (SCI).3 SCI is defined as a subjective memory or cognitive complaint that is not corroborated by psychometric or mental status tests.4,5 However, emerging data indicate that subtle neuropsychological abnormalities can occur in persons with subjective memory complaint.6,7 The description of SCI was derived from studies that used the Global Deterioration Scale (GDS) to define cognitive and functional status between normal aging and dementia.8 The GDS classifies persons on an ordinal scale spanning from GDS 1 to 7. Reisberg proposed six criteria for primary idiopathic SCI: 1) subjective cognitive deficits; 2) the subject’s belief that he or she has experienced a decline in cognitive function compared with previous years; 3) no medical, neurological, or psychiatric conditions that can account for the subjective cognitive complaint; 4) no overt cognitive deficits that might be elicited in the context of a detailed clinical interview or might be evident to a knowledgeable informant; 5) normal cognitive performance on objective testing; and 6) no dementia.4
In the past, memory complaint or SCI was generally assumed to be a manifestation of depression; however, this assertion did not withstand empirical scrutiny, because investigators have reported that SCI cannot be attributed to a psychiatric condition.5,9 Furthermore, emerging data indicate that SCI is associated with both chemical10 and neuroimaging biomarkers of AD.11–13
Apolipoprotein E ε4 (APOE ε4) is a well-known risk factor for sporadic and familial late-onset AD.14–16 It is also a risk factor for mild cognitive impairment (MCI) due to AD.17,18 APOE ε4 is a prognostic factor for the clinical progression of AD.19,20 However, it remains unclear whether APOE ε4 is also a risk factor for SCI. Few studies have examined the association between the construct of memory complaints and APOE ε4,21–25 whereas we used Reisberg’s definition of SCI in order to investigate the association of SCI with APOE ε4 genotype.
Thus, the objective of our study was to examine the association between APOE ε4 genotype and SCI, as defined by the Reisberg criteria, among participants who are classified as cognitively normal by an expert consensus panel after reviewing data from the neurological examination and objective neuropsychological tests.26
Methods
Design, Setting, and Study Sample
This case-control study was derived from the Arizona APOE cohort study, which was conducted at the Mayo Clinic in Scottsdale, Arizona.26 From Jan. 1, 1994, through Aug. 6, 2007, cognitively normal residents 21 years of age and older from Maricopa County were recruited through local media advertisements. Eligible participants for the current analyses were all cognitively normal persons for whom APOE ε4 data were available. Participants with MCI or dementia were excluded. All cognitively normal persons who were APOE ε4 carriers were classified as cases, whereas all cognitively normal persons who were not carriers of the APOE ε4 allele were classified as controls. Written informed consent was obtained from all study participants. The study was conducted with the approval of the institutional review board of the Mayo Clinic in Scottsdale, Arizona.
Assessment of SCI
Study participants completed a validated, self-reported Memory Frequency Questionnaire (MFQ).27,28 The MFQ has 64 items with ordinal responses ranging from 1 (extreme difficulty with a memory item) to 7 (no difficulty at all with a memory item). The questionnaire assesses the ability to recall names (language), recognize familiar faces, follow directions to places, recall events within the past several months to years, etc. The first question of the MFQ is the main item and inquires about memory as follows: “How would you rate your memory in terms of the kinds of problems that you have? Rate the problem from 1 (major problems) to 7 (no problems) with 4 being related to minor problems.” A cognitively normal person who was defined as having normal results on neurological examination and neuropsychological tests26 and who also scored less than 7 points on this main item was classified in the SCI category.
Measurement of APOE Genotype
After informed consent was obtained, blood was drawn from the study participants. We determined APOE ε4 genotypes from DNA using a polymerase chain reaction amplification.29 Cases and controls were not aware of their APOE ε4 status.
Neuropsychological Tests
The study participants underwent the following evaluations: acquisition of medical history, neurological examination, and a structured psychiatric interview. The tests administered include the Folstein Mini-Mental State Examination (MMSE),30,31 the Hamilton Depression Rating Scale (HAM-D),32 a Functional Activities Questionnaire (FAQ),33 and Instrumental Activities of Daily Living Questionnaire (IADL).34 Neuropsychological testing was performed to assess four cognitive domains (memory, executive functions, language, and spatial skills). The standardized battery of neuropsychological tests included the long-term memory score on the Auditory Verbal Learning Test (AVLT-LTM),35 the Controlled Oral Word Association Test (COWAT) for evaluation of executive and language skills,36 and the Judgment of Line Orientation (JLO) test for evaluation of visuospatial function.36 Relevant information was provided by the participants as well as an informant, who was usually the spouse. The entry criteria for this study included a score of ≥27 on the MMSE (and a score of ≥1 out of 3 on the recall subtest), a score of ≤10 on the HAM-D rating scale, and normal function according to the FAQ and the IADL scale.26 A consensus panel of behavioral neurologists determined the cognitive status of each participant after reviewing neurological and neuropsychological data, and based on published criteria of MCI18,37 and DSM-IV criteria for dementia. A description of the neuropsychological and behavioral tests that were administered to the participants of the APOE cohort study is also provided elsewhere.26
Statistical Analysis
We used two-sample t tests to compare means of continuous variables, and percentages were compared using the Pearson chi-square test. We conducted a multivariable logistic regression analysis in order to calculate odds ratios and 95% confidence intervals (95% CI) after adjusting for age, sex, education, and marital status. We then used the odds ratio (95% CI) to compare the “risk” for SCI between the two groups (cognitively normal participants who are APOE ε4 carriers versus noncarriers). Statistical testing was performed at the conventional two-tailed alpha level of 0.05. We conducted our analyses using SAS software (SAS Institute, Cary, N.C.).
Results
Demographics
There were 114 cognitively normal persons for whom relevant data from the MFQ were available. The participants ranged in age from 24 to 91 years with a mean (SD) age of 69.1 (9.5) years. In regard to the frequency and distribution of APOE genotypes, 6 participants were APOE ε2/ε3 carriers, 61 participants were APOE ε3/ε3 carriers, and 47 participants (41%) carried the APOE ε4 allele. Of these 47 APOE ε4 carriers, 3 persons had APOE ε2/ε4, 38 persons had APOE ε3/ε4, and 6 persons had APOE ε4/ε4. There were no group differences (APOE ε4 carrier versus noncarrier) in age, sex, and marital status. Where there was a group difference (education), adjusting for it by analysis did not appreciably alter the odds ratio (Table 1).
| Variable | APOE ε4 Carrier (N=47) | APOE ε4 Noncarrier (N=67) | Odds Ratio (95% CI) | p |
|---|---|---|---|---|
| Age (years), mean (SD) | 69.7 (9.4) | 68.7 (9.6) | — | 0.60 |
| Age >70 years, N (%) | 24 (51) | 32 (48) | 1.14 (0.54–2.40) | 0.73 |
| Female, N (%) | 32 (68) | 51 (76) | 0.67 (0.29–1.54) | 0.34 |
| Married, N (%) | 35 (74) | 40 (60) | 1.97 (0.87–4.50) | 0.10 |
| Education (years), mean (SD) | 17.0 (2.3) | 16.0 (2.5) | — | 0.04 |
| Education >16 years, N (%) | 24 (51) | 28 (42) | 1.45 (0.69–3.10) | 0.33 |
Key Findings
SCI was common among both cases and controls, i.e., 43/46 (93%) APOE ε4 carriers and 52/65 (80%) noncarriers reported SCI as defined by a score of <7 on the main item of the MFQ (odds ratio: 3.6, 95% CI: 0.96–13). Adjustment for age, sex, educational level, and marital status slightly reduced the odds ratio to 3.2 (95% CI: 0.82–12). All but one (83%) of the six APOE ε4 homozygotes reported SCI. When comparing only cases and controls older than 70 years of age, 23/23 (100%) APOE ε4 carriers and 23/30 (77%) noncarriers reported SCI (Table 2). The odds of having SCI were significantly higher among carriers than among noncarriers (odds ratio approaches infinity; p=0.02) in this age group. No significant difference was observed in the frequency of SCI between carriers (20/23; 87%) and noncarriers (29/35; 83%) ages ≤70 years (odds ratio: 1.38, 95% CI: 0.31–6.2).
| Variable | APOE ε4 Carrier | APOE ε4 Noncarrier | Odds Ratio (95% CI) | p |
|---|---|---|---|---|
| All | 43/46 (93%) | 52/65 (80%) | 3.6 (0.96–13) | 0.046 |
| Age >70 years | 23/23 (100%) | 23/30 (77%) | —b | 0.02 |
| Age ≤70 years | 20/23 (87%) | 29/35 (83%) | 1.38 (0.31–6.2) | >0.99 |
a
Three participants (one APOE ε4 carrier, two APOE ε4 noncarriers) had a missing value for the MFQ main item. Those three participants had complete data for the remaining items on the MFQ.
b
The odds ratio approaches infinity.
Discussion
Here we report that the odds of having SCI are dependent on APOE ε4 carrier status and age such that cognitively normal individuals who are APOE ε4 carriers and are older than 70 years of age have an increased odds of experiencing SCI. The odds of having SCI are not increased in persons who are 70 years of age and younger even if they are APOE ε4 carriers.
APOE ε4 is a risk factor for AD and MCI; however, it is unknown whether this allele is also a risk factor for SCI. Furthermore, we conducted a stratified analysis by age group in order to investigate whether SCI is dependent on both APOE ε4 and age. The relationships between APOE ε4 and similar constructs such as “subjective memory complaint” or “subjective memory impairment” have been reported. Although these constructs may not be identical with SCI, the results of those studies are still important contributions to the field of SCI.
Consistent with our findings, Wang et al.38 recently reported a slightly higher frequency of the APOE ε4 allele in 17 individuals with SCI compared with 75 normal controls. Similarly, Blesa et al.21 observed a higher frequency of the APOE ε4 allele in 27 persons with memory complaints without dementia compared with 35 healthy controls. Additionally, a multicentered study that involved a sample of 39 cognitively normal persons ages 50–82 years reported that participants who were APOE ε4 carriers (N=19) had an increased subjective memory impairment compared with noncarriers (N=20).23 Laws et al.22 conducted a study to investigate the difference in APOE ε4 genotype between 98 elderly individuals with memory complaints and 49 controls. They also found that persons with subjective memory complaints exhibited a significantly higher frequency of the APOE ε4 allele compared with the controls. Investigators from the Longitudinal Aging Study Amsterdam reported a slightly but not significantly higher proportion of APOE ε4 carriers among participants who expressed memory complaints.25
Discrepant findings of no association between APOE ε4 and memory complaints have also been reported. For example, Harwood et al.24 did not observe an association between APOE ε4 genotype and subjective memory complaints as assessed by using a memory questionnaire in a sample of 232 older adults who were 60 years of age or older. The discrepancy between their observations and our finding may be due to methodological differences. Importantly, it should be noted that the Harwood et al. study included participants 60 years of age and older, whereas our study demonstrates that the association between APOE ε4 carrier status and SCI was evident only in participants older than 70 years of age. Thus, it is tempting to speculate that the results of the Harwood et al. study might have yielded associations between the variables if age had been stratified differently.
The strength of our study is that participants were recruited from the Arizona APOE cohort, where participants undergo extensive and detailed evaluations pertaining to neurological, psychiatric, and cognitive variables. The limitation of our study pertained to the study design. Case-control studies can be used to test hypotheses. However, causal inference is stronger when case-control findings are confirmed in a prospective cohort study. We further assessed SCI based on a self-reported, validated questionnaire. Recall bias may therefore be present in this study. Our findings should thus be considered as preliminary until they are confirmed in a prospective cohort study with a larger sample size.
Conclusions
We observed that the odds of having SCI are higher in cognitively normal individuals who are APOE ε4 carriers and who are also older than 70 years of age. This finding contributes to the growing body of research that identifies APOE ε4 as an important risk factor of cognitive decline and AD. Further research, especially population-based prospective cohort studies, is needed to confirm these findings.
Acknowledgments
Supported by the Robert Wood Johnson Foundation and in part by NIMH grants K01 MH068351 and R01 MH057899; National Institute on Aging grants P30 AG19610 and R01 AG031581; Alzheimer’s Association grant IIRG-98-078; the Arizona Alzheimer’s Consortium and the State of Arizona; the European Regional Development Fund FNUSA-ICRC (No. CZ.1.05/1.1.00/02.0123); the Edli Foundation (The Hague, the Netherlands); and the Institute of Sports and Sports Science, Karlsruhe Institute of Technology, Karlsruhe, Germany.
Footnote
Dr. Acosta performed the work while she was an employee of Mayo Clinic. Currently, she is a full-time employee of Piramal Pharma, Inc., Boston, MA.
References
1.
Dubois B, Feldman HH, Jacova C, et al: Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol 2010; 9:1118–1127
2.
Sperling RA, Aisen PS, Beckett LA, et al: Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7:280–292
3.
Reisberg B, Gauthier S: Current evidence for subjective cognitive impairment (SCI) as the pre-mild cognitive impairment (MCI) stage of subsequently manifest Alzheimer’s disease. Int Psychogeriatr 2008; 20:1–16
4.
Reisberg B, Prichep L, Mosconi L, et al: The pre-mild cognitive impairment, subjective cognitive impairment stage of Alzheimer’s disease. Alzheimers Dement 2008; 4(Suppl 1):S98–S108
5.
Reisberg B, Shulman MB: Commentary on “a roadmap for the prevention of dementia II: Leon Thal Symposium 2008.” Subjective cognitive impairment as an antecedent of Alzheimer’s dementia: policy import. Alzheimers Dement 2009; 5:154–156
6.
Amariglio RE, Townsend MK, Grodstein F, et al: Specific subjective memory complaints in older persons may indicate poor cognitive function. J Am Geriatr Soc 2011; 59:1612–1617
7.
Steinberg SI, Negash S, Sammel MD, et al: Subjective memory complaints, cognitive performance, and psychological factors in healthy older adults. Am J Alzheimers Dis Other Demen 2013; 28:776–783
8.
Reisberg B, Ferris SH, de Leon MJ, et al: The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982; 139:1136–1139
9.
Caselli RJ, Chen K, Locke DE, et al: Subjective cognitive decline: self and informant comparisons. Alzheimers Dement 2014; 10:93–98
10.
Visser PJ, Verhey F, Knol DL, et al: Prevalence and prognostic value of CSF markers of Alzheimer’s disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol 2009; 8:619–627
11.
Stewart R, Dufouil C, Godin O, et al: Neuroimaging correlates of subjective memory deficits in a community population. Neurology 2008; 70:1601–1607
12.
Perrotin A, Mormino EC, Madison CM, et al: Subjective cognition and amyloid deposition imaging: a Pittsburgh Compound B positron emission tomography study in normal elderly individuals. Arch Neurol 2012; 69:223–229
13.
Saykin AJ, Wishart HA, Rabin LA, et al: Older adults with cognitive complaints show brain atrophy similar to that of amnestic MCI. Neurology 2006; 67:834–842
14.
Corder EH, Saunders AM, Strittmatter WJ, et al: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 1993; 261:921–923
15.
Saunders AM, Strittmatter WJ, Schmechel D, et al: Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer’s disease. Neurology 1993; 43:1467–1472
16.
Roses AD: Apolipoprotein E alleles as risk factors in Alzheimer’s disease. Annu Rev Med 1996; 47:387–400
17.
Boyle PA, Buchman AS, Wilson RS, et al: The APOE epsilon4 allele is associated with incident mild cognitive impairment among community-dwelling older persons. Neuroepidemiology 2010; 34:43–49
18.
Petersen RC, Smith GE, Waring SC, et al: Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56:303–308
19.
Petersen RC, Smith GE, Ivnik RJ, et al: Apolipoprotein E status as a predictor of the development of Alzheimer’s disease in memory-impaired individuals. JAMA 1995; 273:1274–1278
20.
Petersen RC, Waring SC, Smith GE, et al: Predictive value of APOE genotyping in incipient Alzheimer’s disease. Ann N Y Acad Sci 1996; 802:58–69
21.
Blesa R, Adroer R, Santacruz P, et al: High apolipoprotein E epsilon 4 allele frequency in age-related memory decline. Ann Neurol 1996; 39:548–551
22.
Laws SM, Clarnette RM, Taddei K, et al: APOE-epsilon4 and APOE -491A polymorphisms in individuals with subjective memory loss. Mol Psychiatry 2002; 7:768–775
23.
Small GW, Chen ST, Komo S, et al: Memory self-appraisal in middle-aged and older adults with the apolipoprotein E-4 allele. Am J Psychiatry 1999; 156:1035–1038
24.
Harwood DG, Barker WW, Ownby RL, et al: No association between subjective memory complaints and apolipoprotein E genotype in cognitively intact elderly. Int J Geriatr Psychiatry 2004; 19:1131–1139
25.
Dik MG, Jonker C, Comijs HC, et al: Memory complaints and APOE-epsilon4 accelerate cognitive decline in cognitively normal elderly. Neurology 2001; 57:2217–2222
26.
Caselli RJ, Dueck AC, Osborne D, et al: Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. N Engl J Med 2009; 361:255–263
27.
Gilewski MJ, Zelinski EM, Schaie KW: The Memory Functioning Questionnaire for assessment of memory complaints in adulthood and old age. Psychol Aging 1990; 5:482–490
28.
Zelinski EM, Gilewski MJ, Anthony-Bergstone CR: Memory Functioning Questionnaire: concurrent validity with memory performance and self-reported memory failures. Psychol Aging 1990; 5:388–399
29.
Hixson JE, Vernier DT: Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990; 31:545–548
30.
Folstein MF, Folstein SE, McHugh PR: “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189–198
31.
Crum RM, Anthony JC, Bassett SS, et al: Population-based norms for the Mini-Mental State Examination by age and educational level. JAMA 1993; 269:2386–2391
32.
Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56–62
33.
Pfeffer RI, Kurosaki TT, Harrah CH Jr, et al: Measurement of functional activities in older adults in the community. J Gerontol 1982; 37:323–329
34.
Lawton MP, Brody EM: Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969; 9:179–186
35.
Rey A: L'examen clinique en psychologie. Paris, France, Presses Universitaires de France, 1964
36.
Lezak MD: Neuropsychological assessment, 4th ed. Oxford, New York, Oxford University Press, 2004
37.
Petersen RC, Morris JC: Mild cognitive impairment as a clinical entity and treatment target. Arch Neurol 2005; 62:1160–1163, discussion 1167
38.
Wang X, Wang H, Li H, et al: Frequency of the apolipoprotein E ε4 allele in a memory clinic cohort in Beijing: a naturalistic descriptive study. PLoS ONE 2014; 9:e99130
Information & Authors
Information
Published In
History
Received: 24 October 2014
Revision received: 6 January 2015
Accepted: 15 January 2015
Published online: 24 March 2015
Published in print: Fall 2015
Authors
Funding Information
European Regional Development Fund: FNUSA-ICRC: CZ.1.05/1.1.00/02.0123
Edli Foundation
Arizona Alzheimer's Consortium
State of Arizona
National Institutes of Health10.13039/100000002: K01 MH068351, P30 AG19610, R01 AG031581, R01 MH057899
Alzheimer's Association10.13039/100000957: IIRG-98-078
Robert Wood Johnson Foundation10.13039/100000867
Department of Sport and Sport Science at Karlsruhe Institute of Technology, Germany
Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
View Options
View options
PDF/EPUB
View PDF/EPUBLogin options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).